title: Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform.
abstract: Display of epitopes on virus-like particles (VLPs) is a highly effective technique for enhancing the immunogenicity of antigens that are poorly immunogenic in their native context. VLP-based vaccines can be used to elicit long-lasting, high-titer antibody responses against diverse target antigens, even self-antigens. Most VLP platform-based vaccines are rationally engineered; specific target epitopes or domains are arrayed so that they are displayed at high-valency on the surface of VLPs. In this review, we describe an alternate technique for vaccine discovery using VLPs. This strategy, analogous to filamentous phage display, allows bacteriophage VLP-based vaccines to be identified from a vast library of potential vaccines by affinity selection. This technology integrates epitope discovery and immunization functions into a single platform.
authors.affiliation: Department of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, NM 87131, United States.
authors.forename: John P
authors.initials: JP
authors.lastname: O'Rourke
authors.affiliation: Department of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, NM 87131, United States.
authors.forename: David S
authors.initials: DS
authors.lastname: Peabody
authors.affiliation: Department of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, NM 87131, United States. Electronic address: bchackerian@salud.unm.edu.
authors.forename: Bryce
authors.initials: B
authors.lastname: Chackerian
mesh_terms: D001435:Bacteriophages / Q000235:genetics*; D061505:Cell Surface Display Techniques / Q000379:methods*; D055808:Drug Discovery / Q000379:methods; D000939:Epitopes / Q000235:genetics / Q000276:immunology*; D006801:Humans; D058425:Vaccines, Virus-Like Particle / Q000235:genetics / Q000276:immunology*
chemical_list: D000939:Epitopes; D058425:Vaccines, Virus-Like Particle
references.citation: Eur J Immunol. 2000 Jan;30(1):128-35
references.pmid: 10602034
references.citation: Science. 2012 Jul 13;337(6091):183-6
references.pmid: 22798606
references.citation: J Immunol. 2002 Dec 1;169(11):6120-6
references.pmid: 12444114
references.citation: Eur J Immunol. 2002 Nov;32(11):3305-14
references.pmid: 12555676
references.citation: FEMS Immunol Med Microbiol. 2003 Jul 15;37(2-3):179-83
references.pmid: 12832123
references.citation: Proc Natl Acad Sci U S A. 1982 Feb;79(3):884-8
references.pmid: 6950432
references.citation: J Immunol. 1985 Jul;135(1):423-7
references.pmid: 3889155
references.citation: J Immunol. 1988 May 15;140(10):3364-72
references.pmid: 2452184
references.citation: J Biol Chem. 1990 Apr 5;265(10):5684-9
references.pmid: 2108146
references.citation: Arch Biochem Biophys. 1997 Nov 1;347(1):85-92
references.pmid: 9344468
references.citation: Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14648-53
references.pmid: 9405667
references.citation: J Virol. 2005 Nov;79(21):13656-66
references.pmid: 16227285
references.citation: Clin Vaccine Immunol. 2006 Oct;13(10):1143-54
references.pmid: 16916959
references.citation: Expert Rev Vaccines. 2007 Jun;6(3):381-90
references.pmid: 17542753
references.citation: Immunol Lett. 2007 Oct 31;113(1):1-5
references.pmid: 17825923
references.citation: Lancet. 2008 Mar 8;371(9615):821-7
references.pmid: 18328929
references.citation: J Immunol. 2008 May 1;180(9):5816-25
references.pmid: 18424700
references.citation: J Mol Biol. 2008 Jun 27;380(1):252-63
references.pmid: 18508079
references.citation: PLoS One. 2008;3(6):e2547
references.pmid: 18575629
references.citation: Biol Chem. 2008 May;389(5):521-36
references.pmid: 18953718
references.citation: Clin Immunol. 2010 Jan;134(1):89-95
references.pmid: 19577521
references.citation: Mol Immunol. 2010 Feb;47(5):1137-48
references.pmid: 20031219
references.citation: Science. 2013 May 31;340(6136):1232910
references.pmid: 23723240
references.citation: Curr Opin Virol. 2013 Jun;3(3):357-62
references.pmid: 23731601
references.citation: Vaccine. 2013 Sep 23;31(41):4647-54
references.pmid: 23933337
references.citation: Biotechnol Bioeng. 2014 Mar;111(3):425-40
references.pmid: 24347238
references.citation: Nature. 2014 Mar 13;507(7491):201-6
references.pmid: 24499818
references.citation: Malar J. 2014;13:326
references.pmid: 25135070
references.citation: PLoS One. 2014;9(11):e111198
references.pmid: 25379726
references.citation: J Infect Dis. 2015 May 1;211(9):1373-5
references.pmid: 25420478
references.citation: Vaccine. 2010 Jun 17;28(27):4384-93
references.pmid: 20434554
references.citation: Immunol Rev. 2010 Jul;236:125-38
references.pmid: 20636813
references.citation: Biotechnol Adv. 2010 Nov-Dec;28(6):849-58
references.pmid: 20659548
references.citation: Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):17880-7
references.pmid: 20876137
references.citation: J Biol Chem. 2011 May 13;286(19):17351-8
references.pmid: 21454495
references.citation: J Mol Biol. 2011 Jun 3;409(2):225-37
references.pmid: 21501621
references.citation: J Mol Biol. 2011 Jun 24;409(5):853-66
references.pmid: 21549714
references.citation: PLoS One. 2011;6(8):e23310
references.pmid: 21858066
references.citation: Eur J Immunol. 2012 Apr;42(4):863-9
references.pmid: 22531913
references.citation: Curr Opin Chem Biol. 2001 Jun;5(3):314-24
references.pmid: 11479124